Form 4: Rigel Pharmaceuticals Director Anthony Lapointe Reports Equity Compensation Grants

Rigel Pharmaceuticals Inc. Director Anthony Gregg Lapointe reported the acquisition of 2,500 shares of common stock through Restricted Stock Units and 3,000 stock options, reflecting recent equity compensation.

Summary

• Anthony Gregg Lapointe, a Director of Rigel Pharmaceuticals Inc. (RIGL), reported changes in his beneficial ownership of company securities.
• On May 23, 2025, Mr. Lapointe acquired 2,500 shares of Common Stock through a Restricted Stock Unit (RSU) award.
• These RSUs are set to fully vest on the date prior to the Company's next Annual Meeting, contingent on Mr. Lapointe's continuous service on the Board of Directors.
• Following this transaction, Mr. Lapointe's direct beneficial ownership of Common Stock stands at 12,500 shares, a number adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
• Additionally, on May 23, 2025, Mr. Lapointe was granted 3,000 stock options with an exercise price of $18.95 per share.
• These stock options vest monthly over one year from the grant date, also subject to his continuous service on the Company's Board of Directors, and have an expiration date of May 23, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates routine equity compensation for a director, aligning their interests with shareholders, which is generally viewed favorably. It does not contain any negative news.

Positives

• The grants of Restricted Stock Units and stock options align the director's interests with those of shareholders, as his compensation is tied to the company's future performance and stock price.
• The acquisition of additional equity by a director can signal confidence in the company's future prospects.

Future Outlook

The Restricted Stock Units are expected to fully vest prior to the company's next Annual Meeting, and the stock options will vest monthly over one year, both contingent on the director's continued service.

Industry Context

This Form 4 filing is a routine disclosure of equity compensation for a director, common practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to incentivize long-term commitment and performance.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.

Next Steps

• Vesting of 2,500 Restricted Stock Units prior to the Company's next Annual Meeting.
• Monthly vesting of 3,000 stock options over one year from the grant date.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Compensation, Beneficial Ownership